PMID- 31955344
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
VI  - 68
IP  - 1
DP  - 2020 Apr
TI  - Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a 
      systematic review and meta-analysis.
PG  - 56-63
LID - 10.1007/s12020-019-02167-6 [doi]
AB  - BACKGROUND: Except conventional treatments, research on medical approach for 
      radioiodine-refractory differentiated thyroid cancer (RR-DTC) was considered 
      particularly challenging. Sorafenib, a novel biological agent, has been widely 
      studied in the treatment of RR-DTC for years. We performed a systematic review 
      and meta-analysis to explore the efficiency and safety of treating RR-DTC 
      patients with sorafenib. METHODS: An electronic search on PubMed/Medline and 
      Embase was carried out to search associated articles. Fixed-effects or 
      random-effects models were chose according to the heterogeneity. RESULTS: A total 
      of 15 eligible studies (636 patients) were included. As shown by the only 
      randomised clinical trial-DECISION, sorafenib significantly improved 
      progression-free survival (PFS) compared with placebo in patients with 
      progressive RR-DTC. The pooled analysis indicated that there were 26% patients 
      (95% CI: 0.19-0.34) achieved partial response (PR), and 44% patients (98% CI: 
      0.39-0.48) achieved stable disease (SD). The most frequent adverse effects (AEs) 
      observed included hand-foot syndrome (HFS), diarrhoea, fatigue, alopecia, weight 
      loss (WS) and rash, the incidence of all grades AEs for which were 71%, 60%, 59%, 
      55%, 51% and 50%, respectively. There were 68% patients (252/368), who had a dose 
      reduction because of the drug toxicities and AEs. CONCLUSIONS: Sorafenib could 
      improve PFS in patients with progressive RR-DTC, comparing with placebo. Due to 
      the resistance to conventional treatments, sorafenib is considered as a promising 
      treatment for RR-DTC by most physicians specialised in this field. However, the 
      use of sorafenib should be cautious due to a high incidence of AEs caused by the 
      agent. More effective agents with less toxicities are warranted.
FAU - Feng, Guoli
AU  - Feng G
AD  - Department of Thyroid & Parathyroid Surgery Center, West China Hospital, Sichuan 
      University, Chengdu, China.
FAU - Luo, Yi
AU  - Luo Y
AD  - Department of Thyroid & Breast Surgery, Affiliated Hospital Of Zunyi Medical 
      University, Zunyi, China.
FAU - Zhang, Qi
AU  - Zhang Q
AD  - Department of Thyroid & Breast Surgery, Affiliated Hospital Of Zunyi Medical 
      University, Zunyi, China.
FAU - Zeng, Feng
AU  - Zeng F
AD  - Department of Thyroid & Breast Surgery, The Second Affiliated Hospital Of Zunyi 
      Medical University, Zunyi, China.
FAU - Xu, Jie
AU  - Xu J
AD  - School of Public Health, Zunyi Medical University, Zunyi, China.
FAU - Zhu, Jingqiang
AU  - Zhu J
AD  - Department of Thyroid & Parathyroid Surgery Center, West China Hospital, Sichuan 
      University, Chengdu, China. jz_wchospital@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200118
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Phenylurea Compounds)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - *Antineoplastic Agents/adverse effects
MH  - Humans
MH  - Iodine Radioisotopes/therapeutic use
MH  - Phenylurea Compounds/adverse effects
MH  - Sorafenib/therapeutic use
MH  - *Thyroid Neoplasms/drug therapy/radiotherapy
OTO - NOTNLM
OT  - Meta-analysis
OT  - Radioiodine-refractory differentiated thyroid cancer (RR-DTC)
OT  - Sorafenib
OT  - Systematic review
EDAT- 2020/01/20 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/01/20 06:00
PHST- 2019/07/11 00:00 [received]
PHST- 2019/12/18 00:00 [accepted]
PHST- 2020/01/20 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/01/20 06:00 [entrez]
AID - 10.1007/s12020-019-02167-6 [pii]
AID - 10.1007/s12020-019-02167-6 [doi]
PST - ppublish
SO  - Endocrine. 2020 Apr;68(1):56-63. doi: 10.1007/s12020-019-02167-6. Epub 2020 Jan 
      18.